Benzinga's Top Upgrades, Downgrades For July 22, 2019

Upgrades

  • For Applied Materials Inc AMAT, Goldman Sachs upgraded the previous rating of Neutral to the current rating Buy. Applied Materials earned $0.70 in the second quarter, compared to $1.22 in the year-ago quarter. Applied Materials's market cap stands at $44,755,176,655. At the moment, the stock has a 52-week-high of $50.39 and a 52-week-low of $28.79. Applied Materials closed at $47.81 at the end of the last trading period.
  • For Amneal Pharmaceuticals Inc AMRX, SVB Leerink upgraded the previous rating of Market Perform to the current rating Outperform. Amneal Pharmaceuticals earned $0.14 in the first quarter. Amneal Pharmaceuticals's market cap stands at $1,016,034,660. At the moment, the stock has a 52-week-high of $24.48 and a 52-week-low of $3.18. Amneal Pharmaceuticals closed at $3.40 at the end of the last trading period.
  • For Caleres Inc CAL, Susquehanna upgraded the previous rating of Neutral to the current rating Positive. Caleres earned $0.36 in the first quarter, compared to $0.43 in the year-ago quarter. Caleres's market cap stands at $760,458,220. At the moment, the stock has a 52-week-high of $41.09 and a 52-week-low of $17.54. Caleres closed at $18.02 at the end of the last trading period.
  • For The Hershey Co HSY, UBS upgraded the previous rating of Sell to the current rating Neutral. Hershey earned $1.59 in the first quarter, compared to $1.41 in the year-ago quarter. Hershey's market cap stands at $30,313,512,861. At the moment, the stock has a 52-week-high of $147.59 and a 52-week-low of $90.52. Hershey closed at $145.20 at the end of the last trading period.
  • For KLA Corp KLAC, Goldman Sachs upgraded the previous rating of Sell to the current rating Neutral. KLA earned $1.80 in the third quarter, compared to $2.02 in the year-ago quarter. KLA's market cap stands at $21,327,409,773. At the moment, the stock has a 52-week-high of $133.95 and a 52-week-low of $80.65. KLA closed at $131.96 at the end of the last trading period.
  • For Lam Research Corp LRCX, Goldman Sachs upgraded the previous rating of Neutral to the current rating Buy. Lam Research earned $3.70 in the third quarter, compared to $4.79 in the year-ago quarter. Lam Research's market cap stands at $29,755,918,210. At the moment, the stock has a 52-week-high of $209.50 and a 52-week-low of $122.64. Lam Research closed at $198.47 at the end of the last trading period.
  • For Micron Technology Inc MU, Goldman Sachs upgraded the previous rating of Neutral to the current rating Buy. Micron Technology earned $1.05 in the third quarter, compared to $3.15 in the year-ago quarter. Micron Technology's market cap stands at $50,245,129,812. At the moment, the stock has a 52-week-high of $57.55 and a 52-week-low of $28.39. Micron Technology closed at $45.52 at the end of the last trading period.
  • For New Media Investment Group Inc NEWM, Citigroup upgraded the previous rating of Neutral to the current rating Buy. New Media Investment Gr earned ($0.15) in the first quarter, compared to ($0.01) in the year-ago quarter. New Media Investment Gr's market cap stands at $593,797,936. At the moment, the stock has a 52-week-high of $18.80 and a 52-week-low of $8.51. New Media Investment Gr closed at $9.82 at the end of the last trading period.
  • For PolyOne Corp POL, Baird upgraded the previous rating of Neutral to the current rating Outperform. PolyOne earned $0.64 in the first quarter, compared to $0.68 in the year-ago quarter. PolyOne's market cap stands at $2,366,358,833. At the moment, the stock has a 52-week-high of $45.70 and a 52-week-low of $24.47. PolyOne closed at $30.42 at the end of the last trading period.
  • For Regions Financial Corp RF, Wedbush upgraded the previous rating of Neutral to the current rating Outperform. Regions Financial earned $0.39 in the second quarter, compared to $0.32 in the year-ago quarter. Regions Financial's market cap stands at $15,330,093,009. At the moment, the stock has a 52-week-high of $19.99 and a 52-week-low of $12.39. Regions Financial closed at $15.12 at the end of the last trading period.
  • For Repligen Corp RGEN, H.C. Wainwright upgraded the previous rating of Neutral to the current rating Buy. Repligen earned $0.28 in the first quarter, compared to $0.17 in the year-ago quarter. Repligen's market cap stands at $4,166,798,412. At the moment, the stock has a 52-week-high of $89.22 and a 52-week-low of $45.00. Repligen closed at $86.80 at the end of the last trading period.
  • For Charles Schwab Corp SCHW, Wells Fargo upgraded the previous rating of Market Perform to the current rating Outperform. Charles Schwab earned $0.66 in the second quarter, compared to $0.60 in the year-ago quarter. Charles Schwab's market cap stands at $57,031,601,397. At the moment, the stock has a 52-week-high of $54.07 and a 52-week-low of $37.83. Charles Schwab closed at $42.74 at the end of the last trading period.
  • For Stitch Fix Inc SFIX, Stifel Nicolaus upgraded the previous rating of Hold to the current rating Buy. Stitch Fix earned $0.07 in the third quarter, compared to $0.09 in the year-ago quarter. Stitch Fix's market cap stands at $2,713,747,615. At the moment, the stock has a 52-week-high of $52.44 and a 52-week-low of $16.05. Stitch Fix closed at $26.90 at the end of the last trading period.

 

Downgrades

  • For Brunswick Corp BC, JP Morgan downgraded the previous rating of Overweight to the current rating Neutral. Brunswick earned $0.99 in the first quarter, compared to $1.01 in the year-ago quarter. Brunswick's market cap stands at $3,981,144,163. At the moment, the stock has a 52-week-high of $69.82 and a 52-week-low of $41.02. Brunswick closed at $45.72 at the end of the last trading period.
  • For FVCBankcorp Inc FVCB, Raymond James downgraded the previous rating of Strong Buy to the current rating Outperform. FVCBankcorp earned $0.28 in the second quarter, compared to $0.26 in the year-ago quarter. FVCBankcorp's market cap stands at $252,923,536. At the moment, the stock has a 52-week-high of $21.20 and a 52-week-low of $15.53. FVCBankcorp closed at $18.35 at the end of the last trading period.
  • For MarineMax Inc HZO, Raymond James downgraded the previous rating of Strong Buy to the current rating Market Perform. MarineMax earned $0.23 in the second quarter, compared to $0.25 in the year-ago quarter. MarineMax's market cap stands at $378,440,009. At the moment, the stock has a 52-week-high of $26.11 and a 52-week-low of $15.34. MarineMax closed at $16.57 at the end of the last trading period.
  • For Intercontinental Exchange Inc ICE, Citigroup downgraded the previous rating of Buy to the current rating Neutral. Intercontinental Exchange earned $0.92 in the first quarter, compared to $0.90 in the year-ago quarter. Intercontinental Exchange's market cap stands at $51,182,027,502. At the moment, the stock has a 52-week-high of $92.31 and a 52-week-low of $69.69. Intercontinental Exchange closed at $90.75 at the end of the last trading period.
  • For Keysight Technologies Inc KEYS, Goldman Sachs downgraded the previous rating of Buy to the current rating Neutral. Keysight Technologies earned $1.22 in the second quarter, compared to $0.83 in the year-ago quarter. Keysight Technologies's market cap stands at $16,457,433,036. At the moment, the stock has a 52-week-high of $94.52 and a 52-week-low of $53.21. Keysight Technologies closed at $87.44 at the end of the last trading period.
  • For LyondellBasell Industries NV LYB, Nomura downgraded the previous rating of Buy to the current rating Neutral. LyondellBasell Industries earned $2.19 in the first quarter, compared to $3.11 in the year-ago quarter. LyondellBasell Industries's market cap stands at $31,818,515,257. At the moment, the stock has a 52-week-high of $116.63 and a 52-week-low of $73.94. LyondellBasell Industries closed at $85.95 at the end of the last trading period.
  • For Malibu Boats Inc MBUU, Raymond James downgraded the previous rating of Strong Buy to the current rating Market Perform. Malibu Boats earned $1.15 in the third quarter, compared to $0.89 in the year-ago quarter. Malibu Boats's market cap stands at $734,167,653. At the moment, the stock has a 52-week-high of $59.57 and a 52-week-low of $32.09. Malibu Boats closed at $35.21 at the end of the last trading period.
  • For MasterCraft Boat Holdings Inc MCFT, Raymond James downgraded the previous rating of Strong Buy to the current rating Market Perform. MasterCraft Boat Hldgs earned $0.78 in the third quarter, compared to $0.56 in the year-ago quarter. MasterCraft Boat Hldgs's market cap stands at $349,957,634. At the moment, the stock has a 52-week-high of $39.50 and a 52-week-low of $17.60. MasterCraft Boat Hldgs closed at $18.69 at the end of the last trading period.
  • For Marvell Technology Group Ltd MRVL, Goldman Sachs downgraded the previous rating of Buy to the current rating Neutral. Marvell Technology Group earned $0.16 in the first quarter, compared to $0.32 in the year-ago quarter. Marvell Technology Group's market cap stands at $17,133,120,000. At the moment, the stock has a 52-week-high of $26.65 and a 52-week-low of $14.34. Marvell Technology Group closed at $25.92 at the end of the last trading period.
  • For M&T Bank Corp MTB, Piper Jaffray downgraded the previous rating of Overweight to the current rating Neutral. M&T Bank earned $3.37 in the second quarter, compared to $3.29 in the year-ago quarter. M&T Bank's market cap stands at $22,251,651,687. At the moment, the stock has a 52-week-high of $180.77 and a 52-week-low of $133.78. M&T Bank closed at $162.86 at the end of the last trading period.
  • For New Age Beverages Corp NBEV, Northland Capital Markets downgraded the previous rating of Outperform to the current rating Market Perform. New Age Beverages earned ($0.02) in the first quarter, compared to ($0.07) in the year-ago quarter. New Age Beverages's market cap stands at $305,340,605. At the moment, the stock has a 52-week-high of $9.99 and a 52-week-low of $1.30. New Age Beverages closed at $4.05 at the end of the last trading period.
  • For Nasdaq Inc NDAQ, Citigroup downgraded the previous rating of Neutral to the current rating Sell. Nasdaq earned $1.22 in the first quarter, compared to $1.24 in the year-ago quarter. Nasdaq's market cap stands at $16,857,119,802. At the moment, the stock has a 52-week-high of $104.69 and a 52-week-low of $75.49. Nasdaq closed at $101.73 at the end of the last trading period.
  • For Universal Display Corp OLED, Roth Capital downgraded the previous rating of Buy to the current rating Neutral. Universal Display earned $0.66 in the first quarter, compared to $0.55 in the year-ago quarter. Universal Display's market cap stands at $9,721,356,765. At the moment, the stock has a 52-week-high of $208.46 and a 52-week-low of $78.78. Universal Display closed at $205.92 at the end of the last trading period.
  • For PaySign Inc PAYS, BTIG Research downgraded the previous rating of Neutral to the current rating Sell. PaySign's market cap stands at $826,558,460. At the moment, the stock has a 52-week-high of $18.67 and a 52-week-low of $2.41. PaySign closed at $17.50 at the end of the last trading period.

 

Initiations

  • Cowen & Co. initiated coverage on Adaptive Biotechnologies Corp ADPT with an Outperform rating. Adaptive Biotechnologies earned $0.06 in the third quarter, compared to $0.31 in the year-ago quarter. Adaptive Biotechnologies's market cap stands at $4,747,829,581. At the moment, the stock has a 52-week-high of $51.00 and a 52-week-low of $36.21. Adaptive Biotechnologies closed at $38.53 at the end of the last trading period.
  • Goldman Sachs initiated coverage on Adaptive Biotechnologies Corp ADPT with a Neutral rating. The price target for Adaptive Biotechnologies is set to $32.00. Adaptive Biotechnologies earned $0.06 in the third quarter, compared to $0.31 in the year-ago quarter. Adaptive Biotechnologies's market cap stands at $4,747,829,581. At the moment, the stock has a 52-week-high of $51.00 and a 52-week-low of $36.21. Adaptive Biotechnologies closed at $38.53 at the end of the last trading period.
  • JP Morgan initiated coverage on Adaptive Biotechnologies Corp ADPT with an Overweight rating. The price target for Adaptive Biotechnologies is set to $45.00. Adaptive Biotechnologies earned $0.06 in the third quarter, compared to $0.31 in the year-ago quarter. Adaptive Biotechnologies's market cap stands at $4,747,829,581. At the moment, the stock has a 52-week-high of $51.00 and a 52-week-low of $36.21. Adaptive Biotechnologies closed at $38.53 at the end of the last trading period.
  • Bank of America initiated coverage on Adaptive Biotechnologies Corp ADPT with a Buy rating. The price target for Adaptive Biotechnologies is set to $45.00. Adaptive Biotechnologies earned $0.06 in the third quarter, compared to $0.31 in the year-ago quarter. Adaptive Biotechnologies's market cap stands at $4,747,829,581. At the moment, the stock has a 52-week-high of $51.00 and a 52-week-low of $36.21. Adaptive Biotechnologies closed at $38.53 at the end of the last trading period.
  • William Blair initiated coverage on Adaptive Biotechnologies Corp ADPT with an Outperform rating. Adaptive Biotechnologies earned $0.06 in the third quarter, compared to $0.31 in the year-ago quarter. Adaptive Biotechnologies's market cap stands at $4,747,829,581. At the moment, the stock has a 52-week-high of $51.00 and a 52-week-low of $36.21. Adaptive Biotechnologies closed at $38.53 at the end of the last trading period.
  • Guggenheim initiated coverage on Adaptive Biotechnologies Corp ADPT with a Buy rating. The price target for Adaptive Biotechnologies is set to $47.00. Adaptive Biotechnologies earned $0.06 in the third quarter, compared to $0.31 in the year-ago quarter. Adaptive Biotechnologies's market cap stands at $4,747,829,581. At the moment, the stock has a 52-week-high of $51.00 and a 52-week-low of $36.21. Adaptive Biotechnologies closed at $38.53 at the end of the last trading period.
  • Citigroup initiated coverage on Autodesk Inc ADSK with a Buy rating. The price target for Autodesk is set to $210.00. Autodesk earned $0.45 in the first quarter, compared to $0.06 in the year-ago quarter. Autodesk's market cap stands at $37,183,791,089. At the moment, the stock has a 52-week-high of $178.95 and a 52-week-low of $117.72. Autodesk closed at $169.31 at the end of the last trading period.
  • Atlantic Equities initiated coverage on Advanced Micro Devices Inc AMD with a Neutral rating. The price target for Advanced Micro Devices is set to $28.00. Advanced Micro Devices earned $0.06 in the first quarter, compared to $0.11 in the year-ago quarter. Advanced Micro Devices's market cap stands at $35,162,839,504. At the moment, the stock has a 52-week-high of $34.86 and a 52-week-low of $15.72. Advanced Micro Devices closed at $32.51 at the end of the last trading period.
  • Citigroup initiated coverage on Ansys Inc ANSS with a Buy rating. Ansys earned $1.29 in the first quarter, compared to $1.20 in the year-ago quarter. Ansys's market cap stands at $17,465,506,907. At the moment, the stock has a 52-week-high of $212.94 and a 52-week-low of $136.80. Ansys closed at $208.10 at the end of the last trading period.
  • H.C. Wainwright initiated coverage on Aspen Aerogels Inc ASPN with a Buy rating. The price target for Aspen Aerogels is set to $10.00. Aspen Aerogels earned ($0.25) in the first quarter, compared to ($0.29) in the year-ago quarter. Aspen Aerogels's market cap stands at $154,937,096. At the moment, the stock has a 52-week-high of $7.50 and a 52-week-low of $1.60. Aspen Aerogels closed at $6.42 at the end of the last trading period.
  • BMO Capital initiated coverage on BridgeBio Pharma Inc BBIO with an Outperform rating. The price target for BridgeBio Pharma is set to $49.00. BridgeBio Pharma's market cap stands at $3,399,547,342. At the moment, the stock has a 52-week-high of $31.64 and a 52-week-low of $24.06. BridgeBio Pharma closed at $27.51 at the end of the last trading period.
  • Piper Jaffray initiated coverage on BridgeBio Pharma Inc BBIO with an Overweight rating. The price target for BridgeBio Pharma is set to $50.00. BridgeBio Pharma's market cap stands at $3,399,547,342. At the moment, the stock has a 52-week-high of $31.64 and a 52-week-low of $24.06. BridgeBio Pharma closed at $27.51 at the end of the last trading period.
  • Goldman Sachs initiated coverage on BridgeBio Pharma Inc BBIO with a Buy rating. The price target for BridgeBio Pharma is set to $42.00. BridgeBio Pharma's market cap stands at $3,399,547,342. At the moment, the stock has a 52-week-high of $31.64 and a 52-week-low of $24.06. BridgeBio Pharma closed at $27.51 at the end of the last trading period.
  • SVB Leerink initiated coverage on BridgeBio Pharma Inc BBIO with an Outperform rating. The price target for BridgeBio Pharma is set to $34.00. BridgeBio Pharma's market cap stands at $3,399,547,342. At the moment, the stock has a 52-week-high of $31.64 and a 52-week-low of $24.06. BridgeBio Pharma closed at $27.51 at the end of the last trading period.
  • Jefferies initiated coverage on BridgeBio Pharma Inc BBIO with a Buy rating. The price target for BridgeBio Pharma is set to $38.00. BridgeBio Pharma's market cap stands at $3,399,547,342. At the moment, the stock has a 52-week-high of $31.64 and a 52-week-low of $24.06. BridgeBio Pharma closed at $27.51 at the end of the last trading period.
  • JP Morgan initiated coverage on BridgeBio Pharma Inc BBIO with an Overweight rating. The price target for BridgeBio Pharma is set to $38.00. BridgeBio Pharma's market cap stands at $3,399,547,342. At the moment, the stock has a 52-week-high of $31.64 and a 52-week-low of $24.06. BridgeBio Pharma closed at $27.51 at the end of the last trading period.
  • Ascendiant initiated coverage on BioHiTech Global Inc BHTG with a Buy rating. The price target for BioHiTech Global is set to $5.00. BioHiTech Global earned ($0.14) in the first quarter, compared to ($0.49) in the year-ago quarter. BioHiTech Global's market cap stands at $26,834,320. At the moment, the stock has a 52-week-high of $4.50 and a 52-week-low of $1.60. BioHiTech Global closed at $1.80 at the end of the last trading period.
  • H.C. Wainwright initiated coverage on BioLife Solutions Inc BLFS with a Buy rating. The price target for BioLife Solutions is set to $23.00. BioLife Solutions earned $0.02 in the first quarter, compared to ($0.01) in the year-ago quarter. BioLife Solutions's market cap stands at $348,836,236. At the moment, the stock has a 52-week-high of $26.35 and a 52-week-low of $9.15. BioLife Solutions closed at $17.53 at the end of the last trading period.
  • Piper Jaffray initiated coverage on Change Healthcare Inc CHNG with an Overweight rating. The price target for Change Healthcare is set to $18.50. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • Wells Fargo initiated coverage on Change Healthcare Inc CHNG with a Market Perform rating. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • Goldman Sachs initiated coverage on Change Healthcare Inc CHNG with a Buy rating. The price target for Change Healthcare is set to $20.00. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • Barclays initiated coverage on Change Healthcare Inc CHNG with an Overweight rating. The price target for Change Healthcare is set to $18.00. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • Cantor Fitzgerald initiated coverage on Change Healthcare Inc CHNG with an Overweight rating. The price target for Change Healthcare is set to $20.00. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • JP Morgan initiated coverage on Change Healthcare Inc CHNG with an Overweight rating. The price target for Change Healthcare is set to $18.00. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • SVB Leerink initiated coverage on Change Healthcare Inc CHNG with an Outperform rating. The price target for Change Healthcare is set to $20.00. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • SunTrust Robinson Humphrey initiated coverage on Change Healthcare Inc CHNG with a Buy rating. The price target for Change Healthcare is set to $21.00. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • Guggenheim initiated coverage on Change Healthcare Inc CHNG with a Buy rating. The price target for Change Healthcare is set to $17.00. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • Cowen & Co. initiated coverage on Change Healthcare Inc CHNG with an Outperform rating. The price target for Change Healthcare is set to $17.00. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • Credit Suisse initiated coverage on Change Healthcare Inc CHNG with an Outperform rating. The price target for Change Healthcare is set to $18.00. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • William Blair initiated coverage on Change Healthcare Inc CHNG with an Outperform rating. Change Healthcare's market cap stands at $1,684,264,954. At the moment, the stock has a 52-week-high of $15.30 and a 52-week-low of $13.28. Change Healthcare closed at $13.50 at the end of the last trading period.
  • Goldman Sachs initiated coverage on Cambium Networks Corp CMBM with a Neutral rating. The price target for Cambium Networks is set to $11.00. Cambium Networks's market cap stands at $267,601,196. At the moment, the stock has a 52-week-high of $10.50 and a 52-week-low of $8.04. Cambium Networks closed at $10.45 at the end of the last trading period.
  • Deutsche Bank initiated coverage on Cambium Networks Corp CMBM with a Hold rating. The price target for Cambium Networks is set to $12.00. Cambium Networks's market cap stands at $267,601,196. At the moment, the stock has a 52-week-high of $10.50 and a 52-week-low of $8.04. Cambium Networks closed at $10.45 at the end of the last trading period.
  • Raymond James initiated coverage on Cambium Networks Corp CMBM with an Outperform rating. The price target for Cambium Networks is set to $12.50. Cambium Networks's market cap stands at $267,601,196. At the moment, the stock has a 52-week-high of $10.50 and a 52-week-low of $8.04. Cambium Networks closed at $10.45 at the end of the last trading period.
  • JP Morgan initiated coverage on Cambium Networks Corp CMBM with an Overweight rating. The price target for Cambium Networks is set to $18.00. Cambium Networks's market cap stands at $267,601,196. At the moment, the stock has a 52-week-high of $10.50 and a 52-week-low of $8.04. Cambium Networks closed at $10.45 at the end of the last trading period.
  • Oppenheimer initiated coverage on Cambium Networks Corp CMBM with an Outperform rating. Cambium Networks's market cap stands at $267,601,196. At the moment, the stock has a 52-week-high of $10.50 and a 52-week-low of $8.04. Cambium Networks closed at $10.45 at the end of the last trading period.
  • Piper Jaffray initiated coverage on Eidos Therapeutics Inc EIDX with an Overweight rating. The price target for Eidos Therapeutics is set to $55.00. Eidos Therapeutics earned ($0.32) in the first quarter. Eidos Therapeutics's market cap stands at $1,283,440,082. At the moment, the stock has a 52-week-high of $41.35 and a 52-week-low of $8.89. Eidos Therapeutics closed at $34.85 at the end of the last trading period.
  • Cantor Fitzgerald initiated coverage on Fate Therapeutics Inc FATE with an Overweight rating. The price target for Fate Therapeutics is set to $32.00. Fate Therapeutics earned ($0.30) in the first quarter, compared to ($0.27) in the year-ago quarter. Fate Therapeutics's market cap stands at $1,393,021,272. At the moment, the stock has a 52-week-high of $22.82 and a 52-week-low of $8.64. Fate Therapeutics closed at $21.37 at the end of the last trading period.
  • Laidlaw & Co. initiated coverage on Galmed Pharmaceuticals Ltd GLMD with a Buy rating. The price target for Galmed Pharmaceuticals is set to $25.00. Galmed Pharmaceuticals earned ($0.17) in the first quarter, compared to ($0.17) in the year-ago quarter. Galmed Pharmaceuticals's market cap stands at $131,745,531. At the moment, the stock has a 52-week-high of $15.98 and a 52-week-low of $5.48. Galmed Pharmaceuticals closed at $6.24 at the end of the last trading period.
  • Atlantic Equities initiated coverage on Intel Corp INTC with an Underweight rating. The price target for Intel is set to $38.00. Intel earned $0.89 in the first quarter, compared to $0.87 in the year-ago quarter. Intel's market cap stands at $225,058,790,000. At the moment, the stock has a 52-week-high of $59.59 and a 52-week-low of $42.36. Intel closed at $50.27 at the end of the last trading period.
  • Compass Point initiated coverage on Investors Real Estate Trust IRET with a Buy rating. The price target for Investors Real Estate is set to $67.50. Investors Real Estate earned $0.77 in the fourth quarter, compared to $0.08 in the year-ago quarter. Investors Real Estate's market cap stands at $701,728,784. At the moment, the stock has a 52-week-high of $62.24 and a 52-week-low of $46.30. Investors Real Estate closed at $59.74 at the end of the last trading period.
  • SunTrust Robinson Humphrey initiated coverage on KBR Inc KBR with a Buy rating. The price target for KBR is set to $37.00. KBR earned $0.36 in the first quarter, compared to $0.34 in the year-ago quarter. KBR's market cap stands at $3,654,051,049. At the moment, the stock has a 52-week-high of $26.31 and a 52-week-low of $13.89. KBR closed at $25.82 at the end of the last trading period.
  • Jefferies initiated coverage on Linx SA LINX with a Buy rating. The price target for Linx is set to $11.00. Linx's market cap stands at $1,464,155,571. At the moment, the stock has a 52-week-high of $9.60 and a 52-week-low of $8.76. Linx closed at $9.11 at the end of the last trading period.
  • National Securities initiated coverage on Limoneira Co LMNR with a Buy rating. The price target for Limoneira is set to $30.00. Limoneira earned ($0.09) in the second quarter, compared to $0.44 in the year-ago quarter. Limoneira's market cap stands at $336,260,486. At the moment, the stock has a 52-week-high of $33.42 and a 52-week-low of $18.07. Limoneira closed at $18.92 at the end of the last trading period.
  • H.C. Wainwright initiated coverage on Microbot Medical Inc MBOT with a Buy rating. The price target for Microbot Medical is set to $10.00. Microbot Medical's market cap stands at $21,667,559. At the moment, the stock has a 52-week-high of $19.40 and a 52-week-low of $1.38. Microbot Medical closed at $5.03 at the end of the last trading period.
  • Guggenheim initiated coverage on McKesson Corp MCK with a Neutral rating. The price target for McKesson is set to $152.00. McKesson earned $3.69 in the fourth quarter, compared to $3.49 in the year-ago quarter. McKesson's market cap stands at $25,887,778,217. At the moment, the stock has a 52-week-high of $148.23 and a 52-week-low of $106.11. McKesson closed at $138.92 at the end of the last trading period.
  • Stifel Nicolaus initiated coverage on Medallia Inc MDLA with a Buy rating. The price target for Medallia is set to $43.00. Medallia's market cap stands at $4,505,427,310. At the moment, the stock has a 52-week-high of $39.56 and a 52-week-low of $32.05. Medallia closed at $37.09 at the end of the last trading period.
  • Jefferies initiated coverage on Micro Focus International PLC MFGP with a Hold rating. The price target for Micro Focus Intl is set to $21.00. Micro Focus Intl's market cap stands at $7,135,474,853. At the moment, the stock has a 52-week-high of $32.93 and a 52-week-low of $17.76. Micro Focus Intl closed at $20.45 at the end of the last trading period.
  • BMO Capital initiated coverage on Morphic Holding Inc MORF with an Outperform rating. The price target for Morphic Holding is set to $30.00. Morphic Holding's market cap stands at $559,371,638. At the moment, the stock has a 52-week-high of $25.19 and a 52-week-low of $15.72. Morphic Holding closed at $18.90 at the end of the last trading period.
  • Jefferies initiated coverage on Morphic Holding Inc MORF with a Buy rating. Morphic Holding's market cap stands at $559,371,638. At the moment, the stock has a 52-week-high of $25.19 and a 52-week-low of $15.72. Morphic Holding closed at $18.90 at the end of the last trading period.
  • RBC Capital initiated coverage on Nexa Resources SA NEXA with a Sector Perform rating. The price target for Nexa Resources is set to $12.00. Nexa Resources earned ($0.11) in the first quarter, compared to $0.41 in the year-ago quarter. Nexa Resources's market cap stands at $1,226,548,719. At the moment, the stock has a 52-week-high of $14.33 and a 52-week-low of $8.22. Nexa Resources closed at $9.20 at the end of the last trading period.
  • RBC Capital initiated coverage on Nexa Resources SA NEXA with a Sector Perform rating. The price target for Nexa Resources is set to $12.00. Nexa Resources earned ($0.11) in the first quarter, compared to $0.41 in the year-ago quarter. Nexa Resources's market cap stands at $1,226,548,719. At the moment, the stock has a 52-week-high of $14.33 and a 52-week-low of $8.22. Nexa Resources closed at $9.20 at the end of the last trading period.
  • Barrington Research initiated coverage on Pluralsight Inc PS with an Outperform rating. Pluralsight earned ($0.07) in the first quarter. Pluralsight's market cap stands at $4,094,599,149. At the moment, the stock has a 52-week-high of $38.37 and a 52-week-low of $17.88. Pluralsight closed at $29.57 at the end of the last trading period.
  • Citigroup initiated coverage on PTC Inc PTC with a Neutral rating. PTC earned $0.22 in the second quarter, compared to $0.34 in the year-ago quarter. PTC's market cap stands at $10,122,531,501. At the moment, the stock has a 52-week-high of $107.44 and a 52-week-low of $76.67. PTC closed at $87.99 at the end of the last trading period.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: UpgradesDowngradesInitiationIntraday UpdateAnalyst RatingsHealth CareHealth Care DistributorsInformation TechnologyInitiationsSemiconductor Equipmenttop upgrades
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!